Multiple Sclerosis: Evaluation of Purine Nucleotide Metabolism in Central Nervous System in Association with Serum Levels of Selected Fat-Soluble Antioxidants

Table 2

CSF levels of purine nucleotide degradation products in patients with multiple sclerosis (MS) and in the control group.

	Control (𝑛=34)	MS (𝑛=42)	𝑃 value
Uric acid (μmol/L)	16.13±3.55	20.45±7.20	0.0029
Hypoxanthine (μmol/L)	2.39±0.84	3.44±1.68	0.0015
Xanthine (μmol/L)	1.67±0.62	2.52±1.02	0.0001
Inosine (μmol/L)	0.91±0.35	1.30±0.40	0.0001
Adenosine (μmol/L)	0.44±0.20	0.20±0.16	0.0000

The mean ± standard deviation is shown.